– ISRAEL, Ra’anana – UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today the appointment of Kathryn “Kate” Falberg to its Board of Directors, effective immediately. Ms. Falberg will also serve as the Chair of the Board’s Audit Committee.
Ms. Falberg brings extensive executive leadership and management experience in the life sciences industry. She most recently served as an Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals PLC. Previously, Ms. Falberg served as Senior Vice President, Finance and Strategy and Chief Financial Officer of Amgen. Ms. Falberg currently serves on the boards of Aimmune Therapeutics, aTyr Pharma, Axovant Sciences, BioMarin Pharmaceutical and The Trade Desk, and recently served on the board of directors of Medivation until its acquisition by Pfizer. Ms. Falberg holds a B.A. and M.B.A from UCLA, is a CPA, inactive, and a UCLA Certified Director.
Arie Belldegrun, MD, Urogen Pharma’s Chairman, commented, “We are extremely pleased to welcome Kate to the UroGen Board of Directors. Kate’s financial and industry expertise and track record make her an excellent choice for UroGen. We look forward to Kate’s contributions and benefitting from her counsel.”
Kate Falberg commented, “I am delighted to have the opportunity to join UroGen’s Board of Directors. UroGen’s dedicated team is developing important cutting edge treatments in the uro-oncology space and I look forward to providing financial leadership and operational guidance as the Company continues to grow.”
About UroGen Pharma Ltd.
UroGen Pharma is a clinical stage biopharmaceutical company developing advanced non-surgical, local treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving the efficacy and safety profiles of existing drugs. UroGen Pharma’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma’s lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. Moreover, UroGen Pharma has recently completed a worldwide licensing agreement with Allergan Pharmaceuticals International Limited, a wholly owned subsidiary of Allergan plc, for the use of RTGel with neurotoxins for the treatment of overactive bladder and related conditions. UroGen Pharma is headquartered in Israel and also maintains a corporate office in New York City.
For more information : http://www.urogen.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.